# The Branded Health Service Medicines (Costs) (Amendment) Regulations 2024, Regulation 11: Amendments to regulation 22


In regulation 22 (presentation report)—
(a) in paragraph (a), after “supplied” insert “and whether it is a newer presentation or an older presentation”;
(b) in paragraphs (b) and (c), for “regulation 3(4)” substitute “regulation 3(4)(a), (b), (c), (d), (g) and (h)”; and
(c) after paragraph (g), insert—
“(ga) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of new active substance presentation supplied;
(gb) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item which is a line extension to which regulation 3(4)(f) applies that is supplied;
(gc) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of exceptional central procurement presentation supplied;
(gd) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of centrally procured vaccine presentation supplied;
(ge) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of presentation of plasma derived medicinal products;
(gf) the quantity supplied and the total gross sales income and the total net sales income received for the supply of each item of presentation to which regulation 3(4A)(b) applies that is supplied;”.

---
Source: https://www.legislation.gov.uk/uksi/2024/1277/regulation/11 (the official version)
Page: https://openlegislation.uk/branded-health-service-medicines-costs-amendment-regulations-2024/regulation-11
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.